
Secher et al. evaluated the risk of pre-eclampsia in pregnant patients with RA, axSpA or PsA, assessing the effect of disease activity and disease-modifying anti-rheumatic drugs on this risk.... [Read More]
Secher et al. evaluated the risk of pre-eclampsia in pregnant patients with RA, axSpA or PsA, assessing the effect of disease activity and disease-modifying anti-rheumatic drugs on this risk.... [Read More]
• By Jason Liebowitz, MD
PHILADELPHIA—Ever since the seminal work of C. Lockard Conley, MD, in 1952 of the discovery of the lupus anticoagulant, antiphospholipid syndrome (APS) has been of great interest to rheumatologists, hematologists and many others. At ACR Convergence 2022, the session titled Draft ACR/EULAR Antiphospholipid Syndrome Classification Criteria sought to summarize the rigorous process that went into… [Read More]
• By Mithu Maheswaranathan, MD
ACR CONVERGENCE 2021—Rheumatologists are often left in a challenging space when managing medications for patients with rheumatic diseases in relation to contraception, pregnancy and breastfeeding, especially with many novel immunosuppressants and often a dearth of pregnancy safety data. On Nov. 6 during ACR Convergence 2021, leading reproductive health experts came together to speak on this… [Read More]
• By Lara C. Pullen, PhD
For women with antiphospholipid syndrome (APS), treatment with a combination of heparin and aspirin during pregnancy—rather than aspirin alone—may increase live birth rates, according to new research.... [Read More]
• By Jason Liebowitz, MD
For patients with lupus, family planning discussions are vital to achieving positive pregnancy outcomes & maintaining overall health…... [Read More]
• By Anat Chemerinski, MD, & Jason Liebowitz, MD
BALTIMORE—Understanding issues regarding pregnancy in women with rheumatic disease is important to patients and physicians alike, said Bonnie Bermas, MD, the Dr. Morris Ziff Distinguished Professor in Rheumatology at UT Southwestern Medical Center, Dallas, in her recent lecture at the Maryland Society for the Rheumatic Diseases.The physiologic changes in normal pregnancy, which include increased circulating… [Read More]
• By David Douglas
NEW YORK (Reuters Health)—Women with a diagnosis of juvenile idiopathic arthritis (JIA) are at increased risk of pregnancy complications, according to Swedish researchers. As Dr. Katarina Remaeus told Reuters Health by email, “In our cohort study . . . we found an association with adverse pregnancy outcomes including preterm birth, induction of labor and delivery… [Read More]
• By Kimberly Retzlaff
The decision to continue or discontinue immunomodulatory medications during pregnancy is a difficult one for both patients and physicians. On the one hand, when left untreated, rheumatic conditions can cause harm to an unborn child, as well as to the pregnant mother. On the other hand, medications can be harmful to a developing fetus. In… [Read More]
• By Lara C. Pullen, PhD
A recent review investigated risk factors for preeclampsia in early pregnancy, finding that antiphospholipid antibody syndrome may be the strongest risk factor. As a result of these findings, researchers have compiled a list of risk factors to help clinicians determine which women are more likely to develop the condition and aid them in weighing treatment options…... [Read More]
• By Imad Uthman, MD, MPH, and Munther Khamashta, MD, PhD
With a wide range of clinical manifestations and frequent occurrence among rheumatology patients, APS is one for rheumatologists to watch... [Read More]
The Foundation is the largest private funding source for rheumatology research and training in the U.S.
Visit the official website for the American College of Rheumatology.
Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.